1Barber MD, Ross JA & Fearon KC (1999) Cancer cachexia. Surg Oncol 8, 133–141.
2Larkin M (1998) Thwarting the dwindling progression of cachexia. Lancet 351, 1336.
3Tisdale MJ (1997) Biology of cachexia. J Natl Cancer Inst 89, 1763–1773.
4Azhar G & Wei JY (2006) Nutrition and cardiac cachexia. Curr Opin Clin Nutr Metab Care 9, 18–23.
5Bosaeus I, Daneryd P & Lundholm K (2002) Dietary intake, resting energy expenditure, weight loss and survival in cancer patients. J Nutr 132, 3465S–3466S.
6Dewys WD, Begg C, Lavin PT, et al. (1980) Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 69, 491–497.
7Kotler DP, Tierney AR, Culpepper-Morgan JA, et al. (1990) Effect of home total parenteral nutrition on body composition in patients with acquired immunodeficiency syndrome. JPEN J Parenter Enteral Nutr 14, 454–458.
8Anker SD & Sharma R (2002) The syndrome of cardiac cachexia. Int J Cardiol 85, 51–66.
9Delano MJ & Moldawer LL (2006) The origins of cachexia in acute and chronic inflammatory diseases. Nutr Clin Pract 21, 68–81.
10Klaude M, Fredriksson K, Tjader I, et al. (2007) Proteasome proteolytic activity in skeletal muscle is increased in patients with sepsis. Clin Sci (Colch) 112, 499–506.
11Melstrom LG, Melstrom KA Jr, Ding XZ, et al. (2007) Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia. Histol Histopathol 22, 805–814.
12Büntzel J & Küttner K (1995) Value of megestrol acetate in treatment of cachexia in head–neck tumors (article in German). Laryngorhinootologie 74, 504–507.
13Lees J (1999) Incidence of weight loss in head and neck cancer patients on commencing radiotherapy treatment at a regional oncology centre. Eur J Cancer Care (Engl) 8, 133–136.
14Palesty JA & Dudrick SJ (2003) What we have learned about cachexia in gastrointestinal cancer. Dig Dis 21, 198–213.
15Jagoe RT & Goldberg AL (2001) What do we really know about the ubiquitin–proteasome pathway in muscle atrophy? Curr Opin Clin Nutr Metab Care 4, 183–190.
16Gomes MD, Lecker SH, Jagoe RT, et al. (2001) Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A 98, 14440–14445.
17Bodine SC, Latres E, Baumhueter S, et al. (2001) Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294, 1704–1708.
18Wray CJ, Mammen JMV, Hershko DD, et al. (2003) Sepsis upregulates the gene expression of multiple ubiquitin ligases in skeletal muscle. Int J Biochem Cell Biol 35, 698–705.
19Lecker SH, Jagoe RT, Gilbert A, et al. (2004) Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J 18, 39–51.
20Dehoux MJM, van Beneden RP, Fernandez-Celemin L, et al. (2003) Induction of MafBx and Murf ubiquitin ligase mRNAs in rat skeletal muscle after LPS injection. FEBS Lett 544, 214–217.
21Jones SW, Hill RJ, Krasney PA, et al. (2004) Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle mass. FASEB J 18, 1025–1027.
22Di Giovanni S, Molon A, Broccolini A, et al. (2004) Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol 55, 195–206.
23Siddiqui R, Pandya D, Harvey K, et al. (2006) Nutrition modulation of cachexia/proteolysis. Nutr Clin Pract 21, 155–161.
24Haslett PA (1998) Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 25, 53–57.
25Ng EH & Lowry SF (1991) Nutritional support and cancer cachexia. Evolving concepts of mechanisms and adjunctive therapies. Hematol Oncol Clin North Am 5, 161–184.
26Inui A (2002) Cancer anorexia–cachexia syndrome: current issues in research and management. CA Cancer J Clin 52, 72–91.
27Ammon HP & Wahl MA (1991) Pharmacology of Curcuma longa. Planta Med 57, 1–7.
28Miquel J, Bernd A, Sempere JM, et al. (2002) The curcuma antioxidants: pharmacological effects and prospects for future clinical use. A review. Arch Gerontol Geriatr 34, 37–46.
29Joe B, Vijaykumar M & Lokesh BR (2004) Biological properties of curcumin – cellular and molecular mechanisms of action. Crit Rev Food Sci Nutr 44, 97–111.
30Goel A, Kunnumakkara AB & Aggarwal BB (2008) Curcumin as ‘Curecumin’: from kitchen to clinic. Biochem Pharmacol 75, 787–809.
31Aggarwal BB, Shishodia S, Takada Y, et al. (2005) Curcumin suppresses the paclitaxel-induced nuclear factor-κB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res 11, 7490–7498.
32Shishodia S, Chaturvedi MM & Aggarwal BB (2007) Role of curcumin in cancer therapy. Curr Probl Cancer 31, 243–305.
33Jana NR, Dikshit P, Goswami A, et al. (2004) Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem 279, 11680–11685.
34Wyke SM, Russell ST & Tisdale MJ (2004) Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-κB activation. Br J Cancer 91, 1742–1750.
35Jin B & Li Y-P (2007) Curcumin prevents lipopolysaccharide-induced atrogin-1/MAFbx upregulation and muscle mass loss. J Cell Biochem 100, 960–969.
36Thaloor D, Miller KJ, Gephart J, et al. (1999) Systemic administration of the NF-κB inhibitor curcumin stimulates muscle regeneration after traumatic injury. Am J Physiol 277, C320–C329.
37Busquets S, Carbo N, Almendro V, et al. (2001) Curcumin, a natural product present in turmeric, decreases tumor growth but does not behave as an anticachectic compound in a rat model. Cancer Lett 167, 33–38.
38Pan MH, Huang TM & Lin JK (1999) Biotransformation of curcumin through reduction and glucuronidation in mice. Drug Metab Dispos 27, 486–494.
39Sharma RA, Euden SA, Platton SL, et al. (2004) Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 10, 6847–6854.
40Lao CD, Ruffin MTIV, Normolle D, et al. (2006) Dose escalation of a curcuminoid formulation. BMC Complement Altern Med 6, 10.
41Garcea G, Berry DP, Jones DJ, et al. (2005) Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 14, 120–125.
42Marczylo TH, Verschoyle RD, Cooke DN, et al. (2007) Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 60, 171–177.
43Whitehouse AS & Tisdale MJ (2003) Increased expression of the ubiquitin–proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-κB. Br J Cancer 89, 1116–1122.
44Beck SA & Tisdale MJ (1987) Production of lipolytic and proteolytic factors by a murine tumor-producing cachexia in the host. Cancer Res 47, 5919–5923.
45Smith HJ, Mukerji P & Tisdale MJ (2005) Attenuation of proteasome-induced proteolysis in skeletal muscle by β-hydroxy-β-methylbutyrate in cancer-induced muscle loss. Cancer Res 65, 277–283.
46Cai D, Frantz JD, Tawa NE Jr, et al. (2004) IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell 119, 285–298.
47Mitch WE & Goldberg AL (1996) Mechanisms of muscle wasting. The role of the ubiquitin–proteasome pathway. N Engl J Med 335, 1897–1905.
48Breen HB & Espat NJ (2004) The ubiquitin–proteasome proteolysis pathway: potential target for disease intervention. JPEN J Parenter Enteral Nutr 28, 272–277.
49Llovera M, Garcia-Martinez C, Agell N, et al. (1995) Muscle wasting associated with cancer cachexia is linked to an important activation of the ATP-dependent ubiquitin-mediated proteolysis. Int J Cancer 61, 138–141.
50Hasselgren PO (1999) Role of the ubiquitin–proteasome pathway in sepsis-induced muscle catabolism. Mol Biol Rep 26, 71–76.
51Llovera M, Carbo N, Lopez-Soriano J, et al. (1998) Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett 133, 83–87.
52Llovera M, Garcia-Martinez C, Agell N, et al. (1997) TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. Biochem Biophys Res Commun 230, 238–241.
53Garcia-Martinez C, Llovera M, Agell N, et al. (1994) Ubiquitin gene expression in skeletal muscle is increased by tumour necrosis factor-α. Biochem Biophys Res Commun 201, 682–686.
54Lecker SH, Solomon V, Mitch WE, et al. (1999) Muscle protein breakdown and the critical role of the ubiquitin–proteasome pathway in normal and disease states. J Nutr 129, 227S–237S.
55Hobler SC, Tiao G, Fischer JE, et al. (1998) Sepsis-induced increase in muscle proteolysis is blocked by specific proteasome inhibitors. Am J Physiol 274, R30–R37.
56Stitt TN, Drujan D, Clarke BA, et al. (2004) The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 14, 395–403.
57Sandri M, Sandri C, Gilbert A, et al. (2004) Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 399–412.
58Latres E, Amini AR, Amini AA, et al. (2005) Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem 280, 2737–2744.
59Li Y-P, Chen Y, John J, et al. (2005) TNF-α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. FASEB J 19, 362–370.
60Li Y-P, Lecker SH, Chen Y, et al. (2003) TNF-α increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E220k. FASEB J 17, 1048–1057.
61Li YP & Reid MB (2000) NF-κB mediates the protein loss induced by TNF-α in differentiated skeletal muscle myotubes. Am J Physiol Regul Integr Comp Physiol 279, R1165–R1170.
62Poylin V, Fareed MU, O'Neal P, et al. (2008) The NF-κB inhibitor curcumin blocks sepsis-induced muscle proteolysis. Mediators Inflamm 2008, 317851.
63Jobin C, Bradham CA, Russo MP, et al. (1999) Curcumin blocks cytokine-mediated NF-κB activation and proinflammatory gene expression by inhibiting inhibitory factor I-κB kinase activity. J Immunol 163, 3474–3483.
64Durham WJ, Arbogast S, Gerken E, et al. (2006) Progressive nuclear factor-κB activation resistant to inhibition by contraction and curcumin in mdx mice. Muscle Nerve 34, 298–303.
65Carter Y, Liu G, Yang J, et al. (2003) Sublethal hemorrhage induces tolerance in animals exposed to cecal ligation and puncture by altering p38, p44/42, and SAPK/JNK MAP kinase activation. Surg Infect (Larchmt) 4, 17–27.